Scarica l'app Stockscreener
4.20
2.10%
-0.09
Dopo l'orario di chiusura:
4.20
Lifecore Biomedical Inc Borsa (LFCR) Ultime notizie
Lifecore Biomedical, Inc. (LFCR) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business (NASDAQ:LFCR) - seekingalpha.com
Lifecore plans customer meetings in Milan this October - Stock Titan
Lifecore Biomedical to Participate at CPHI Global Conference - GlobeNewswire
Lifecore Strikes Tech Transfer Deal for Commercial Manufacturing of Major Pharma Company Injectable - Contract Pharma
Lifecore Biomedical Signs New Commercial Transfer Agreement for Marketed Injectable Product - Quiver Quantitative
A marketed injectable drug is expected to bring Lifecore revenue in 2028. - Stock Titan
LFCR Q2 2026 Earnings: Narrower Loss of -$0.19 Beats Estimates, Shares Dip 1.35%Revenue Guidance Update - vinanet.vn
Lifecore (LFCR) Results at a Glance: EPS Lands Above Forecast in Latest Trading; Session Move: Shares Rise 0.22% at the CloseEarnings Season Preview - vinanet.vn
Lifecore (LFCR) Earnings Reading: EPS Prints Above Forecast at the Close; After Results: Shares Move 2.42% Down on the DayGuidance Downgrade Alert - vinanet.vn
LFCR | Lifecore Biomedical, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Lifecore Biomedical Earnings Call Balances Growth and Strain - TipRanks
Lifecore (LFCR) Quarterly Scorecard: EPS Beats Its Estimate; The Stock Records a 1.83% Increase on the DayROA Comparison - vinanet.vn
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com
Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity - Yahoo Finance
Avoiding Lag: Real-Time Signals in (LFCR) Movement - news.stocktradersdaily.com
LFCR Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 16.59% EPS SurpriseAnalyst Coverage Count - vinanet.vn
Lifecore Biomedical (LFCR) Holds Above $4.50 Support as Shares Edge LowerSell Signal Alerts - vinanet.vn
LFCR Q2 2026 Earnings: Narrower-than-Expected Loss Offers Modest EncouragementGuidance vs Actual - vinanet.vn
Judge approves $3.75 million Lifecore investor settlement - Minnesota Lawyer
William Blair Maintains Lifecore Biomedical(LFCR.US) With Buy Rating - Moomoo
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com
Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Discipline and Rules-Based Execution in LFCR Response - Stock Traders Daily
Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com
LFCR: Revenue and profit declined, but cost cuts and new wins support strong long-term growth outlook - TradingView
Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lifecore Biomedical Q2 Earnings Call Highlights - MarketBeat
Lifecore Biomedical, Inc. (LFCR) Q2 FY2026 earnings call transcript - Yahoo Finance
LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed - tradingview.com
Lifecore Biomedical Backs 2026 Adj EBITDA of $20.5M-$25M >LFCR - Moomoo
Lifecore Biomedical Q2 revenue falls to $34.2 million as loss widens - Quiver Quantitative
Lifecore Biomedical 2026: Revenue $34.17M, EPS ($0.19) — 10-Q Summary - TradingView
Lifecore Biomedical: Q2 Earnings Snapshot - marketscreener.com
Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed - Stock Titan
Lifecore Biomedical Reports Financial Results for the - GlobeNewswire
LFCR: Q2 2026 delivered strong revenue, margin expansion, and robust pipeline growth - TradingView
Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million - Bitget
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
LFCR Q1 2026 Earnings: Wider-than-Expected Loss Overshadows the QuarterEstimate Dispersion - careplusvn.com
Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to Hold - MarketBeat
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 - GlobeNewswire
LFCR Q1 2026 Earnings: Significant Earnings Miss Amid Operational ChallengesAnalyst Earnings Estimate - careplusvn.com
Lifecore Biomedical (LFCR) Tests Resistance After a Modest UptickBull Flag - dars.gov.et
Lifecore Biomedical signs three new customer de... - Pluang
Lifecore Biomedical Signs Three New Customer Agreements - The Manila Times
Lifecore Biomedical Announces Three New Customer Agreements Spanning Late-Stage Regenerative Medicine and Early-Stage Development Programs - Quiver Quantitative
Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lifecore Biomedical Inc (LFCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LFCR|Lifecore Biomedical Inc|Price:4.330|Chg%:-0.100 - TradingKey
Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lifecore Biomedical (LFCR) Faces Selling Pressure as Stock Tests Key SupportSwing Trade Setups - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical - The National Law Review
Lifecore Biomedical, Inc. Revenue Breakdown – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) Pulls Back: Testing Key Support After 2.26% DeclineSector Leader Stocks - careplusvn.com
0.18%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):